Today: 19 November 2025
Subscribe
Browse Category

Clinical Trials News 17 September 2025 - 17 October 2025

Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

PRAX Stock Soars on Historic Trial Win Praxis Precision Medicines stock has seen a record-breaking spike in recent days after announcing landmark clinical trial results. On October 16, PRAX shares closed at $162.71, up about 183% in a single session ts2.tech ts2.tech. The stock, which had closed at $57.35 the day prior, more than tripled to reach new 52-week highs ts2.tech. Intra-day, PRAX briefly touched as high as $205 as enthusiasm peaked google.com. By midday Thursday, the company was on track to add roughly $2.7 billion to its market capitalization if gains held ts2.tech – catapulting Praxis’s valuation from around $1 billion
17 October 2025
 ·  ·  ·  ·  · 
Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision Medicines (PRAX) Stock Skyrockets 180% on Game‑Changing Trial – Analysts See ‘Blockbuster’ Upside

Record Stock Surge on Phase 3 Breakthrough Praxis Precision Medicines shares skyrocketed on October 16, 2025, after the biotech reported game-changing Phase 3 trial results for its essential tremor drug. The stock closed that Thursday at $162.71, up over 183% in a single day medcitynews.com. Earlier that morning, Praxis announced that ulixacaltamide – its experimental therapy for essential tremor – had succeeded in two pivotal late-stage studies. The news sent PRAX stock soaring more than threefold before the opening bell reuters.com reuters.com, smashing its previous highs. By midday, Reuters estimated Praxis was on track to add about $2.67 billion to its market
17 October 2025
 ·  ·  ·  · 
Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Recent News and Pipeline Developments Theriva Biologics (NYSE American: TOVX) has been in the news for its upcoming conference presentations and strong trial data. On October 13, 2025 the company announced that expanded data from the VIRAGE Phase 2b trial (metastatic pancreatic cancer) will be presented at the ESMO 2025 Congress on October 20 sec.gov. In VIRAGE, the oncolytic adenovirus VCN-01 is given with gemcitabine/nab‑paclitaxel standard chemotherapy. Interim abstract data (recently filed with the SEC) show that VCN-01 + chemotherapy substantially improved overall survival (OS) and progression-free survival (PFS) versus chemotherapy alone sec.gov sec.gov. Patients receiving VCN-01 saw median OS up to
15 October 2025
 ·  ·  ·  · 
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Company Overview Protagonist Therapeutics is a clinical-stage biopharma company leveraging peptide technology to create new medicines for rare hematologic conditions and prevalent immunological diseases protagonist-inc.com. Founded in 2008, Protagonist has built its identity around engineered peptide drugs – a niche between small molecules and antibodies – to tackle challenging targets with oral or injectable therapies. The company’s mission centers on “developing groundbreaking new medicines to treat both rare and prevalent diseases” using its proprietary peptide platform protagonist-inc.com. This focus has led to a pipeline addressing blood cancers/disorders and inflammatory bowel and skin diseases, where current treatments are inadequate. Leadership &
11 October 2025
 ·  ·  ·  · 
Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Recent News and Corporate Developments J&J Buyout Buzz: The biggest news propelling Protagonist’s stock is the report that Johnson & Johnson is in talks to acquire Protagonist reuters.com. On October 10, 2025, The Wall Street Journal broke the story (later confirmed by Reuters) that J&J is negotiating a purchase of Protagonist Therapeutics reuters.com. This potential acquisition would build on the companies’ ongoing partnership: J&J’s Janssen unit has held exclusive worldwide rights to develop and commercialize Protagonist’s peptide drug Icotrokinra (JNJ-2113) since a 2017 collaboration deal reuters.com. In fact, J&J already holds rights to market Icotrokinra and reportedly owns a ~4% stake in Protagonist, reflecting its early
10 October 2025
 ·  ·  ·  ·  · 
Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Dyne Therapeutics Skyrockets on Breakthrough Data – Inside the Surge, Financials & 2026 Catalysts

Recent Stock Performance & Surge on Data Dyne Therapeutics’ stock has been on a tear following its latest clinical breakthroughs. Shares jumped 10–11% intraday on October 7, 2025, after the company reported positive one-year results from a key trial, lifting the stock to about $14.02 by mid-day marketbeat.com marketbeat.com. This rally builds on a strong upward trend in recent months – the stock traded below $8 in spring 2025, so it has nearly doubled since then. Trading volume actually dipped on the spike (about 331,000 shares vs. a 2.6 million average), indicating the price jolt came on limited activity marketbeat.com
7 October 2025
 ·  ·  ·  ·  · 
Biotech Bombshell: MoonLake (MLTX) Shares Tumble 85% on Trial News – Is a $108 Price Target Still Real?

Biotech Bombshell: MoonLake (MLTX) Shares Tumble 85% on Trial News – Is a $108 Price Target Still Real?

Sources: Company filings and press releases globenewswire.com stocktitan.net; financial media (Reuters, Investing.com, Stocktwits, Seeking Alpha) reuters.com stocktwits.com investing.com; market data services stocktitan.net tipranks.com. All figures and quotes are from cited reports.
29 September 2025
 ·  ·  ·  ·  ·  · 
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly’s Weight-Loss Pill Sheds Pounds Fast—But Hits a Plateau: What New Trial Results Mean for the Obesity Drug Race

Trial Results: Big Early Losses, Then Weight Loss Levels Off This highly anticipated trial put Lilly’s oral GLP-1 drug, orforglipron, to the test in a large group of adults struggling with obesity. The study enrolled 3,127 overweight or obese participants (none had diabetes, but all had weight-related health issues) and randomly assigned them to various daily doses of the pill or a placebo for 72 weeks reuters.com. The outcomes were encouraging yet mixed. Patients on the highest dose (36 mg daily) lost on average about 11–12% of their starting body weight by week 72 theguardian.com. In practical terms, that’s roughly
17 September 2025
 ·  ·  ·  ·  ·  · 
1 2 3
Go toTop